10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
|Articles|August 11, 2011
- ONCOLOGY Vol 25 No 9
- Volume 25
- Issue 9
Supplemental Figures for "Cancer and Healthcare Reform: Making the Pieces Fit"
Author(s)Thomas Main, MBA, Andrew Chadwick-jones, MA
Advertisement
Note:These supplemental figures provide concrete illustrations of a
Articles in this issue
about 15 years ago
Management of DCIS-A Work in Progressabout 15 years ago
Tailored Strategies for DCIS Managementabout 15 years ago
Neuroendocrine Tumors: a Heterogeneous Set of Neoplasmsabout 15 years ago
Can We Know What to Do When DCIS Is Diagnosed?about 15 years ago
A Rare Case of Metastatic Renal Epithelioid Angiomyolipomaabout 15 years ago
The Changing Field of Locoregional Treatment for Breast Cancerabout 15 years ago
Cancer and Healthcare Reform: Making the Pieces Fitabout 15 years ago
An Approach to the Management of Rare TumorsAdvertisement
Related to this article
Ayal Aizer, MD, MHS, explains why fractionated SRS outperformed single-fraction SRS for surgical bed control in Alliance A071801.
Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.
“To me, the biggest differentiator might be how the patient wants to experience care,” said Krish Patel, MD, on treatment options for patients with lymphoma.
Ayal Aizer, MD, MHS, says Alliance A071801 supports fractionated SRS as standard after resection, with comparable radiation necrosis rates.
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
2
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
3
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
4
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
5